Clinical approval for the second harvest of Johnson & Johnson cagregyne
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The processing status of jxhl13000468 was changed to CFDA approval on December 16, indicating that the acceptance will be approved clinically According to insight database, caglejing has made three clinical applications in China, which is the second time to obtain clinical approval As a single therapeutic drug, cagregyne is an SGLT2 inhibitor, which is effective for type 2 diabetes patients who cannot be controlled through diet and exercise It was first listed in the United States in March 2013 and in the European Union in November of the same year Both of them are SGLT2 inhibitors and are in phase III clinical practice In addition, there are as many as 10 domestic enterprises applying for caglejing as per category 3.1, including Jiangsu Haosen, Sichuan Kelun, Yangtze River, Zhengda Tianqing, Shandong Luoxin, Jiangsu Xiansheng and other large pharmaceutical enterprises The competition is fierce
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
